Blood tests for heart health and high cholesterol
For people with high cholesterol, a family history of early heart disease, or anyone taking a statin or other cholesterol medicine.
11 tests explainedAI-verified against cited sources. Awaiting expert reviewLast reviewed 2026-10-19
For heart health, the lipid panel is the starting point, and LDL cholesterol is the main number treatment aims to lower. The 2026 U.S. cholesterol guideline sets goals for LDL and non-HDL cholesterol, recommends measuring Lp(a) at least once in all adults, and finds ApoB useful for some people. On cholesterol medicine, a repeat lipid panel shows how well it is working, and a few other tests are checked only when there is a reason.
The tests that matter most
Most important first. Each one links to its full page, where the note for this group sits near the top.
LDL Cholesterol
LDL is the main number cholesterol treatment aims to lower, and the 2026 U.S. guideline sets LDL goals that depend on overall heart risk. It suggests a repeat lipid test 4 to 12 weeks after starting or stepping up cholesterol treatment, to see how well it is working.
Source: Circulation (2026)
- Usual adult range
- up to 99 mg/dL
Non-HDL Cholesterol
Non-HDL cholesterol is total cholesterol minus HDL, so it counts the cholesterol in all the particles that can build plaque. The 2026 U.S. guideline sets non-HDL goals next to LDL goals, each 30 mg/dL above the matching LDL goal, and supports reporting it with every lipid panel.
Source: Circulation (2026)
- Usual adult range
- up to 129 mg/dL
Apolipoprotein B (ApoB)
ApoB counts plaque-building particles, since each one carries a single ApoB. The 2026 U.S. guideline says ApoB can be useful on treatment once LDL and non-HDL goals are met, especially with diabetes, high triglycerides or heart disease, because LDL and ApoB disagree more often in those cases.
Source: Circulation (2026)
- Usual adult range
- up to 90 mg/dL
Lipoprotein(a), molar (nmol/L)
Lp(a) is mostly inherited. The 2026 U.S. guideline recommends measuring it at least once in all adults, counts a high level as a risk-enhancing factor, and prefers tests reported in nmol/L. It says one test is generally enough, unless something can shift the level, such as the menopause transition, pregnancy, or kidney, liver or thyroid disease.
Source: Circulation (2026)
- Usual adult range
- up to 75 nmol/L
Lipoprotein(a), mass (mg/dL)
Some labs report Lp(a) in mg/dL instead of nmol/L. The 2026 U.S. guideline notes that results from different tests and labs are hard to compare, so it helps to compare results in the same unit from the same kind of test.
Source: Circulation (2026)
- Usual adult range
- up to 29.9 mg/dL
Triglycerides
Triglycerides that stay raised count as a risk-enhancing factor in the 2026 U.S. guideline. Clinicians often look for common contributors first, such as alcohol, diet, diabetes that isn't well controlled, kidney disease, an underactive thyroid or some medicines.
Source: Circulation (2026)
- Usual adult range
- up to 149 mg/dL
HDL Cholesterol
HDL is measured in every standard lipid panel. It is needed to work out non-HDL cholesterol, which is total cholesterol minus HDL.
Source: Circulation (2026)
- Usual adult range
- 40 and above mg/dL
C-Reactive Protein (CRP, incl. hs-CRP)
High-sensitivity CRP (hs-CRP) picks up very small rises in CRP and is used to estimate heart risk. If it is measured, the 2026 U.S. guideline counts an hs-CRP of 2 mg/L or more on more than one occasion as a risk-enhancing factor.
Sources: MedlinePlus and Circulation (2026)
- Usual adult range
- 0–5 mg/L
Hemoglobin A1c (HbA1c)
The 2026 U.S. guideline notes that statins slightly raise the chance of type 2 diabetes in people who already have risk factors for it, such as an A1c of 6.0 to 6.4%, and that this is rare with normal blood sugar. The atorvastatin label also lists rises in A1c and fasting glucose.
Sources: Circulation (2026) and U.S. Food and Drug Administration (2024)
- Usual adult range
- 4.8–5.6 %
Alanine Aminotransferase (ALT)
ALT is a liver enzyme. The atorvastatin (Lipitor) label suggests considering liver enzyme tests before starting, and after that when there is a clinical reason.
- Men, 18+
- 0–44 U/L
- Women, 18+
- 0–32 U/L
Creatine Kinase (CK), Total
CK is a muscle enzyme. The atorvastatin label asks people to report unexplained muscle pain, tenderness or weakness. The 2026 U.S. guideline suggests checking CK when muscle symptoms are severe, and notes that muscle aches with a normal CK are common on statins.
Sources: U.S. Food and Drug Administration (2024) and Circulation (2026)
- Men, 19–49
- 26–366 U/L
- Women, 19–49
- 20–239 U/L
Ranges shown are the usual adult ranges labs print. The range on your own report is the one your result is judged against.
Getting results you can compare
- Fasting is usually not needed for a lipid panel. If triglycerides come back at 400 mg/dL or higher on a non-fasting test, a fasting repeat helps estimate LDL.
Sources: Circulation (2026) and Circulation (2026)
- After starting or stepping up cholesterol medicine, the 2026 U.S. guideline suggests a repeat lipid test at 4 to 12 weeks, then every 6 to 12 months. When treatment and results are stable, it considers once a year appropriate.
Source: Circulation (2026)
- Infections, injuries and flares of inflammatory conditions also raise CRP, MedlinePlus notes. The 2026 U.S. guideline counts a raised hs-CRP only when it is high on more than one occasion with no other cause found.
Sources: MedlinePlus and Circulation (2026)
Good to know
- LDL and ApoB can disagree, most often with diabetes, high triglycerides or other heart and metabolic conditions. The 2026 U.S. guideline says ApoB predicts heart risk more accurately than LDL when they disagree, and that non-HDL cholesterol disagrees with ApoB less often than LDL does.
Source: Circulation (2026)
- A high Lp(a) is mostly inherited, so the 2026 U.S. guideline treats it as a reason for early, careful control of the heart risks that can change, including LDL.
Source: Circulation (2026)
- Advanced lipoprotein tests, such as particle counts and sizes, usually add little beyond a standard lipid panel, ApoB and Lp(a). The 2026 U.S. guideline suggests keeping them for cases where the result is likely to change the treatment plan.
Source: Circulation (2026)
Questions you could ask
- What LDL and non-HDL goals fit my overall heart risk?
- Has my Lp(a) ever been measured, and does it need repeating?
- Would an ApoB test add anything in my situation?
- When should we recheck my lipids after this change?
- Which symptoms are worth reporting while I take this medicine?
Sources
- 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia, Circulation (2026)
- Lipid Profile Testing and Interpretation, Circulation (2026)
- LIPITOR (atorvastatin calcium) tablets: prescribing information (revised 4/2024), U.S. Food and Drug Administration (2024)
- C-Reactive Protein (CRP) Test, MedlinePlus
AI-verified against cited sources. Awaiting expert review. Last reviewed 2026-10-19. How we build and check these pages.
Educational information, not medical advice. Blood Test Tracker doesn’t diagnose or treat, and it doesn’t replace your clinician. Talk with your clinician before changing medications, supplements or care.